Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
RedHill Biopharma Ltd is a drug manufacturers-specialty & generic business based in the US. RedHill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. RedHill Biopharma employs 155 staff and has a trailing 12-month revenue of around USD$44.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced investors
52-week range | USD$3.2621 - USD$11.52 |
---|---|
50-day moving average | USD$8.9201 |
200-day moving average | USD$8.9567 |
Wall St. target price | USD$22 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.47 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$44.5 million |
---|---|
Gross profit TTM | USD$4 million |
Return on assets TTM | -32.82% |
Return on equity TTM | -246.27% |
Profit margin | -142.81% |
Book value | $0.771 |
Market capitalisation | USD$324.4 million |
TTM: trailing 12 months
There are currently 2.4 million RedHill Biopharma shares held short by investors – that's known as RedHill Biopharma's "short interest". This figure is 5.9% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting RedHill Biopharma shares can be evaluated.
RedHill Biopharma's "short interest ratio" (SIR) is the quantity of RedHill Biopharma shares currently shorted divided by the average quantity of RedHill Biopharma shares traded daily (recently around 759826.81388013). RedHill Biopharma's SIR currently stands at 3.17. In other words for every 100,000 RedHill Biopharma shares traded daily on the market, roughly 3170 shares are currently held short.
However RedHill Biopharma's short interest can also be evaluated against the total number of RedHill Biopharma shares, or, against the total number of tradable RedHill Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RedHill Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 RedHill Biopharma shares in existence, roughly 60 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable RedHill Biopharma shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against RedHill Biopharma.
Find out more about how you can short RedHill Biopharma stock.
We're not expecting RedHill Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, RedHill Biopharma's shares have ranged in value from as little as $3.2621 up to $11.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RedHill Biopharma's is 1.6217. This would suggest that RedHill Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.